The change follows a landmark guideline published jointly in 2024 by NICE, the British Thoracic Society (BTS) and the Scottish Intercollegiate Guidelines Network (SIGN).
Dr Adrian Hayter joins NICE from the Royal College of General Practitioners bringing more than three decades of frontline clinical and national leadership experience to the role.
We’ve recommended a new treatment called rozanolixizumab for some adults living with generalised myasthenia gravis (gMG) whose symptoms are not controlled by existing treatments.
A new targeted treatment for a rare and aggressive form of bile duct cancer has been recommended by NICE for routine use on the NHS in England, giving people more time with better quality of life.
In Dudley, an asthma clinic is catching people before they reach crisis point, diagnosing faster and making sure patients have the right treatment from the start - referral times have fallen from over a year to under 6 weeks.
NICE-recommended healthtech found the cause of Peter’s stroke. Read his story and discover how our guidance is helping life-changing innovations reach the patients who need them.
Learn how the MHRA and NICE are getting medicines to patients 3 to 6 months sooner by delivering same time decisions on licensing and value.
Sophie Cooper, senior scientific adviser in NICE’s science policy team, explains the importance of the recently published EQ-5D-5L value set and how it has the potential to help us decide if new treatments offer good value for money for the NHS.
